Cybin selects GAD as target indication for deuterated DMT molecule CYB004

Cybin announced that it has selected Generalized Anxiety Disorder, GAD, with or without major depressive disorder, MDD, as the target indication for its proprietary deuterated N, N-dimethyltryptamine, DMT, molecule, CYB004. "Based on preclinical data, CYB004 has shown promise in treating anxiety disorders. About half of people suffering from depression are also burdened with GAD, which makes the need for more effective treatment options for GAD even more urgent," said Doug Drysdale, Chief Executive Officer of Cybin. "Since the pandemic, the prevalence of depression and anxiety has been significantly elevated, and we are optimistic that through our current development programs, Cybin has the potential to provide innovative therapeutics to alleviate the mental suffering that so many people experience worldwide. We remain focused on the opportunity that CYB004, as a new chemical entity, may be able to provide a new path toward mental healing."